TScan Therapeutics Q3 EPS $(0.24) Beats $(0.45) Estimate, Sales $3.89M Miss $4.09M Estimate
Portfolio Pulse from Benzinga Newsdesk
TScan Therapeutics (NASDAQ:TCRX) reported Q3 earnings per share (EPS) of $(0.24), beating the analyst consensus estimate of $(0.45) by 46.67%. However, the company's quarterly sales of $3.89 million missed the analyst consensus estimate of $4.09 million by 4.96%. Compared to the same period last year, the EPS increased by 64.18% and sales increased by 15.58%.
November 09, 2023 | 12:28 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
TScan Therapeutics reported better than expected Q3 EPS but missed on sales. EPS increased by 64.18% YoY, while sales increased by 15.58% YoY.
TScan Therapeutics reported a better than expected EPS, which is a positive signal for investors. However, the company missed on sales, which could be a concern. The YoY increase in both EPS and sales indicates growth, but the missed sales estimate may temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100